Abstract:Background: Metastatic breast cancer (MBC) prognosis is variable, depending on several clinical and biological factors. A better prediction of a patient's outcome could allow for a more accurate choice of treatments. The role of serum biomarkers in predicting outcome remains unclear in this setting. Tau, a microtubule-associated protein, is a neuronal marker that is also expressed in normal breast epithelial cells and cancer cells. Its tissue expression is associated with prognosis in MBC. However, the prognostic value of Tau serum levels in these patients is unknown. We aimed at evaluating the prognostic value of Tau (and other classical biomarkers) in MBC patients, and to assess its association with the presence of brain metastases (BM). Methods: 244 MBC patients treated at our institution (2007-2015) were retrospectively selected. The usual MBC clinical and pathological variables were collected, altogether with CA15-3, CEA and HER2 extra-cellular domain (ECD) serum levels. Tau serum levels were measured with a novel immunoassay (digital ELISA) using Single Molecule Array (Simoa) technology. Overall survival (OS) was estimated with the Kaplan-Meier method. To investigate prognostic factors, a multivariate analysis was performed. Cut-offs were set using the Youden index method associated with receiver-operating characteristics (ROC) curves to evaluate the accuracy of biomarkers to identify patients with BM. Results: With a median follow-up of 40.8 months, median OS was 15.5 months (95%CI 12.4-20.2). Elevated serum levels of Tau were independently associated with a poor outcome in the whole population as well as in patients with (n = 86) and without BM (n = 158). Median serum Tau levels tended to be higher in patients with BM (p = 0.23). In univariate analysis, patients with BM had an increased risk of serum Tau > 3.17 pg/mL (OR = 2.2, p = 0.049). In multivariate analysis, high values of Tau (OR = 3.98, p = 0.034) accurately identified patients with BM in our cohort. Conclusions: Tau is a new biomarker of interest in MBC. Its serum level could represent an independent prognostic factor in these patients (both with and without BM). It also seems to be associated with the presence of BM. A validation of these results in an independent set of MBC patients is necessary to confirm these findings.

Predictive Value of Microtubule-Associated Protein Tau in Patients with Recurrent and Metastatic Breast Cancer Treated with Taxane-Containing Palliative Chemotherapy

Tau proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy

Expression of Tau protein in breast cancer and its clinical analysis

Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer

Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy

Dichotomous role of microtubule associated protein tau as a biomarker of response to and a target for increasing efficacy of taxane treatment in cancers of epithelial origin

Analysis of Tau Protein Expression in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Different Molecular Subtypes of Breast Cancer (vol 23, pg 47, 2020)

RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference Between Mrna and Protein Expression in Predicting Prognosis of Breast Cancer Patients

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases

Combination of Microtubule Associated Protein-Tau and Β-Tubulin III Predicts Chemosensitivity of Paclitaxel in Patients with Advanced Gastric Cancer.

Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.

Protein profiling predicts the response to anthracycline and taxanes based neo-adjuvant chemotherapy in breast cancer

TUBB 3 as molecular marker for improved taxane efficacy of adjuvant chemotherapy for breast cancer

Measuring Beta-Tubulin Iii, Bcl-2, And Ercc1 Improves Pathological Complete Remission Predictive Accuracy In Breast Cancer

Analysis of Tau Protein Expression in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Different Molecular Subtypes of Breast Cancer

Taurine Inhibits Lung Metastasis in Triple-Negative Breast Cancer by Modulating Macrophage Polarization Through PTEN-PI3K/Akt/mTOR Pathway

Tau and stathmin proteins in breast cancer: A potential therapeutic target

Relationship Between Mrna Expression of BRCA1 and Β-Tubulin III in Malignant Effusions and Ex Vivo Chemosenstitivity to Docetaxel

Sensitivity research on Tau gene expression and the use of paclitaxel in the treatment of gastric cancer

Measurement of Molecular Biomarkers That Predict the Tumor Response in Estrogen Receptor-Positive Breast Cancers after Dose-Dense (biweekly) Paclitaxel/carboplatin Neoadjuvant Chemotherapy

Beta-Tubulin III Mrna Expression and Docetaxel Sensitivity in Non-Small Cell Lung Cancer